Amman, June 2 - The Senate Health, Environment, and Population Committee, chaired by Senator Dr. Yassin Al-Hasban, visited Dar Al Dawa Development and Investment Company on Monday.
The committee met with the company's Chairman of the Board of Directors, Akram Jarrab, its CEO, Dr. Khaled Harb, and a number of managers. The committee also toured the company's factory facilities and research and development laboratories, and reviewed manufacturing and analysis technologies, as well as control and quality assurance systems.
Al-Hasban stated that the visit stemmed from the committee's keenness to maintain direct communication with healthcare and pharmaceutical sector institutions and to explore the challenges and opportunities facing this vital sector to achieve drug security.
He expressed the committee's readiness to support leading national companies by enhancing coordination with relevant authorities and following up on relevant issues at the legislative and regulatory levels, ensuring continued growth and development in the pharmaceutical sector.
Al-Hasban praised Dar Al Dawa's distinguished presence in Arab and regional markets, emphasizing that its excellence reflects the competence of Jordanian cadres and the company's ability to compete globally in a sensitive and strategic sector such as the pharmaceutical sector. He pointed out that Jordan was among the first countries in the region to establish a strong base for the pharmaceutical industry and the medical sector in general. This constitutes a national heritage that must be preserved and developed, especially in light of the rapid health and economic transformations and challenges the world is witnessing.
For his part, Jarrab said that such visits embody the important role of cooperation between the private and public sectors, emphasizing the importance of continuing such visits to address the sector's most significant challenges.
For his part, Harb gave a comprehensive presentation on the company's origins and development, explaining that it was founded in 1975 as one of the first Jordanian pharmaceutical manufacturers, and that it is located on an area of 106,000 square meters.
He pointed out that the company has expanded regionally, and now owns seven factories: four in Jordan and three in Algeria, in addition to a branch in the Kingdom of Saudi Arabia. He explained that a license was recently obtained to establish a pharmaceutical production plant in the Saudi market.
Harb confirmed that Dar Al Dawa has obtained more than 16 local and international accreditations, noting that this confirms the company's commitment to the highest standards of quality and pharmaceutical manufacturing.
He explained that the company's exports amounted to approximately JOD 87 million last year, contributing 11 percent of the total employment in the Jordanian pharmaceutical industry and providing job opportunities for more than 1,000 employees, engineers, and technicians.